PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
March 22, 2024Cancer Research

Abstract 2361: A PD1-antibody-attenuated IL-2 fusion protein activates immune cells leading to the inhibition of tumor growth in ex vivo human 3D tumor models

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRonit Satchi‐FainaroOAOpal AvramoffAKAnshika Katyal

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Satchi‐Fainaro et al. (2024) studied this question.

synapsesocial.com/papers/68e72ce8b6db6435876a6f87https://doi.org/10.1158/1538-7445.am2024-2361
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 4057: Beyond IL-2: The promise of anti PD-1-attenuated IL-2 fusion protein in cancer immunotherapy2024
  2. 2Abstract 2473: A novel anti-PD-1 and proIL-2 bifunctional fusion protein delivers potent anti-tumor activity via PD-1 checkpoint inhibition and tumor selective IL-2R agonism preferentially on antigen specific T cells2024
  3. 3Abstract 719: A tumor-activated PD1/IL2 bispecific molecule, designed to overcome IL-2 receptor-mediated clearance, improve tolerability and stimulate antigen-experienced CD8+ T cells in the tumor microenvironment of murine models2024 · 1 citations
  4. 4Abstract 2631: LPD002, a novel anti-PD-1/IL-2 fusion protein, demonstrates potent antitumor activity in preclinical studies.2026
  5. 5Abstract 4058: Nanoparticle delivery of interleukin-2 induces anti-tumor immune response and therapeutic efficacy in mouse tumor models2024